|
Public Act 094-0800 |
HB4300 Enrolled |
LRB094 12962 RLC 47811 b |
|
|
AN ACT concerning criminal law.
|
Be it enacted by the People of the State of Illinois,
|
represented in the General Assembly:
|
Section 5. The Illinois Controlled Substances Act is |
amended by changing Sections 201 and 206 and by adding Section |
218 as follows:
|
(720 ILCS 570/201) (from Ch. 56 1/2, par. 1201)
|
Sec. 201. (a) The Department shall carry out the provisions |
of
this Article. The Department or its successor agency
may add |
substances
to or delete or reschedule all controlled substances |
in the Schedules of
Sections 204, 206, 208, 210 and 212 of this |
Act. In making a determination
regarding the addition,
|
deletion, or rescheduling of a substance, the Department
shall |
consider
the following:
|
(1) the actual or relative potential for abuse;
|
(2) the scientific evidence of its pharmacological |
effect, if known;
|
(3) the state of current scientific knowledge |
regarding the
substance;
|
(4) the history and current pattern of abuse;
|
(5) the scope, duration, and significance of abuse;
|
(6) the risk to the public health;
|
(7) the potential of the substance to produce |
psychological or
physiological dependence;
|
(8) whether the substance is an immediate precursor of |
a substance
already controlled under this Article;
|
(9) the immediate harmful effect in terms of |
potentially fatal
dosage; and
|
(10) the long-range effects in terms of permanent |
health impairment.
|
(b) (Blank).
|
(c) (Blank).
|
|
(d) If any substance is scheduled, rescheduled, or
deleted |
as a
controlled substance under Federal law and notice thereof |
is given to
the Department, the Department shall
similarly |
control the substance
under this Act after the expiration of 30 |
days from publication in the
Federal Register of a final order |
scheduling a substance as
a
controlled substance or |
rescheduling or deleting a substance, unless
within that 30 day |
period the Department objects, or
a party adversely
affected |
files with the Department substantial written objections
|
objecting to inclusion, rescheduling, or deletion. In that |
case, the
Department shall publish the reasons for objection or |
the substantial
written objections and afford all interested |
parties an opportunity to
be heard. At the conclusion of the |
hearing, the Department shall
publish its decision, by means of |
a rule, which shall be final unless
altered by statute. Upon |
publication of objections by the Department, similar control
|
under this Act whether by inclusion, rescheduling or deletion |
is stayed
until the Department publishes its ruling.
|
(e) The Department shall by rule exclude any non-narcotic
|
substances
from a schedule if such substance may, under the |
Federal Food, Drug, and
Cosmetic Act, be lawfully sold over the |
counter without a prescription.
|
(f) The sale, delivery, distribution, and possession of a |
drug product containing dextromethorphan shall be in |
accordance with Section 218 of this Act.
Dextromethorphan shall |
not be deemed to be included in any
schedule by reason of |
enactment of this title unless controlled after
the date of |
such enactment pursuant to the foregoing provisions of this
|
section .
|
(g) Authority to control under this section does not extend |
to
distilled spirits, wine, malt beverages, or tobacco as those |
terms are
defined or used in the Liquor Control Act and the |
Tobacco Products Tax
Act.
|
(h) Persons registered with the Drug Enforcement |
Administration to manufacture or distribute controlled |
substances shall maintain adequate security and provide |
|
effective controls and procedures to guard against theft and |
diversion, but shall not otherwise be required to meet the |
physical security control requirements (such as cage or vault) |
for Schedule V controlled substances containing |
pseudoephedrine or Schedule II controlled substances |
containing dextromethorphan.
|
(Source: P.A. 91-714, eff. 6-2-00.)
|
(720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
|
Sec. 206. (a) The controlled substances listed in this |
Section are
included in Schedule II.
|
(b) Unless specifically excepted or unless listed in |
another
schedule, any of the following substances whether |
produced directly or
indirectly by extraction from substances |
of vegetable origin, or
independently by means of chemical |
synthesis, or by combination of
extraction and chemical |
synthesis:
|
(1) Opium and opiates, and any salt, compound, |
derivative or
preparation of opium or opiate, excluding |
apomorphine, dextrorphan,
levopropoxyphene,
nalbuphine, |
nalmefene, naloxone, and naltrexone, and their respective
|
salts, but including the following:
|
(i) Raw Opium;
|
(ii) Opium extracts;
|
(iii) Opium fluid extracts;
|
(iv) Powdered opium;
|
(v) Granulated opium;
|
(vi) Tincture of opium;
|
(vii) Codeine;
|
(viii) Ethylmorphine;
|
(ix) Etorphine Hydrochloride;
|
(x) Hydrocodone;
|
(xi) Hydromorphone;
|
(xii) Metopon;
|
(xiii) Morphine;
|
(xiv) Oxycodone;
|
|
(xv) Oxymorphone;
|
(xvi) Thebaine;
|
(xvii) Thebaine-derived butorphanol.
|
(xviii) Dextromethorphan subject to Section 218 of |
this Act.
|
(2) Any salt, compound, isomer, derivative or |
preparation thereof
which is chemically equivalent or |
identical with any of the substances
referred to in |
subparagraph (1), but not including the isoquinoline
|
alkaloids of opium;
|
(3) Opium poppy and poppy straw;
|
(4) Coca leaves and any salt, compound, isomer, salt of |
an isomer,
derivative, or preparation of coca leaves |
including cocaine or ecgonine,
and any salt, compound, |
isomer, derivative, or preparation thereof which is
|
chemically equivalent or identical with any of these |
substances, but not
including decocainized coca leaves or |
extractions of coca leaves which do
not contain cocaine or |
ecgonine (for the purpose of this paragraph, the
term |
"isomer" includes optical, positional and geometric |
isomers);
|
(5) Concentrate of poppy straw (the crude extract of |
poppy straw in
either liquid, solid or powder form which |
contains the phenanthrine
alkaloids of the opium poppy).
|
(c) Unless specifically excepted or unless listed in |
another
schedule any of the following opiates, including their |
isomers, esters,
ethers, salts, and salts of isomers, whenever |
the existence of these
isomers, esters, ethers and salts is |
possible within the specific
chemical designation, dextrorphan |
excepted:
|
(1) Alfentanil;
|
(1.1) Carfentanil;
|
(2) Alphaprodine;
|
(3) Anileridine;
|
(4) Bezitramide;
|
(5) Bulk Dextropropoxyphene (non-dosage forms);
|
|
(6) Dihydrocodeine;
|
(7) Diphenoxylate;
|
(8) Fentanyl;
|
(9) Sufentanil;
|
(9.5) Remifentanil;
|
(10) Isomethadone;
|
(11) Levomethorphan;
|
(12) Levorphanol (Levorphan);
|
(13) Metazocine;
|
(14) Methadone;
|
(15) Methadone-Intermediate,
|
4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
|
(16) Moramide-Intermediate,
|
2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
|
acid;
|
(17) Pethidine (meperidine);
|
(18) Pethidine-Intermediate-A,
|
4-cyano-1-methyl-4-phenylpiperidine;
|
(19) Pethidine-Intermediate-B,
|
ethyl-4-phenylpiperidine-4-carboxylate;
|
(20) Pethidine-Intermediate-C,
|
1-methyl-4-phenylpiperidine-4-carboxylic acid;
|
(21) Phenazocine;
|
(22) Piminodine;
|
(23) Racemethorphan;
|
(24) Racemorphan;
|
(25) Levo-alphacetylmethadol (some other names:
|
levo-alpha-acetylmethadol,
levomethadyl acetate, LAAM).
|
(d) Unless specifically excepted or unless listed in |
another
schedule, any material, compound, mixture, or |
preparation which contains
any quantity of the following |
substances having a stimulant effect on
the central nervous |
system:
|
(1) Amphetamine, its salts, optical isomers, and salts |
of its
optical isomers;
|
(2) Methamphetamine, its salts, isomers, and salts of |
|
its isomers;
|
(3) Phenmetrazine and its salts;
|
(4) Methylphenidate.
|
(e) Unless specifically excepted or unless listed in |
another
schedule, any material, compound, mixture, or |
preparation which contains
any quantity of the following |
substances having a depressant effect on
the central nervous |
system, including its salts, isomers, and salts of
isomers |
whenever the existence of such salts, isomers, and salts of
|
isomers is possible within the specific chemical designation:
|
(1) Amobarbital;
|
(2) Secobarbital;
|
(3) Pentobarbital;
|
(4) Pentazocine;
|
(5) Phencyclidine;
|
(6) Gluthethimide;
|
(7) (Blank).
|
(f) Unless specifically excepted or unless listed in |
another schedule,
any material, compound, mixture, or |
preparation which contains any quantity
of the following |
substances:
|
(1) Immediate precursor to amphetamine and |
methamphetamine:
|
(i) Phenylacetone
|
Some trade or other names: phenyl-2-propanone;
|
P2P; benzyl methyl ketone; methyl benzyl ketone.
|
(2) Immediate precursors to phencyclidine:
|
(i) l-phenylcyclohexylamine;
|
(ii) l-piperidinocyclohexanecarbonitrile (PCC).
|
(3) Nabilone.
|
(Source: P.A. 91-714, eff. 6-2-00.)
|
(720 ILCS 570/218 new) |
Sec. 218. Dextromethorphan. |
(a) A drug product containing dextromethorphan may not be |
sold, delivered, distributed, or possessed except in |
|
accordance with the prescription requirements of Sections 309, |
312, and 313 of this Act. |
(b) Possession of a drug product containing |
dextromethorphan in violation of this Section is a Class 4 |
felony. The sale, delivery, distribution, or possession with |
intent to sell, deliver, or distribute a drug product |
containing dextromethorphan in violation of this Section is a |
Class 2 felony. |
(c) This Section does not apply to a drug product |
containing dextromethorphan that is sold in solid, tablet, |
liquid, capsule, powder, thin film, or gel form and which is |
formulated, packaged, and sold in dosages and concentrations |
for use as an over-the-counter drug product. For the purposes |
of this Section, "over-the-counter drug product" means a drug |
that is available to consumers without a prescription and sold |
in compliance with the safety and labeling standards as set |
forth by the United States Food and Drug Administration.
|